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Capreomycin is used for the treatment of multidrug-resistant tuberculosis (MDR-TB), but it is limited
therapeutically by its severe side effects. The objectives of the present studies were (i) to design low-density
porous capreomycin sulfate particles for efficient pulmonary delivery to improve local and systemic drug
bioavailability and capacity to reduce the bacillary load in the lungs in a manner similar to that achieved with
intramuscular injections; (ii) to determine pharmacokinetic parameters after pulmonary administration of
these capreomycin particles; and (iii) to evaluate the efficacy of these particles in treating animals in a
small-aerosol-inoculum guinea pig model of TB. Capreomycin particles were manufactured by spray drying
and characterized in terms of size and drug content. Pharmacokinetic parameters were determined by
noncompartmental methods with healthy guinea pigs after administration of capreomycin particles by insuf-
flation. The efficacy of the particles was evaluated by histopathological analysis and in terms of wet organ
weight and bacterial burden in TB-infected animals. Lungs of animals receiving a 14.5-mg/kg dose of capreo-
mycin particles showed significantly lower wet weights and smaller bacterial burdens than those of animals
receiving any other treatment. These results were supported by histopathological analysis. The feasibility of
inhaling capreomycin in a novel powder form, with the ultimate objective of the treatment of MDR-TB, is
demonstrated by pharmacokinetic and pharmacodynamic studies with guinea pigs. If applied to humans with
MDR-TB, such a therapeutic approach might simplify drug delivery by eliminating injections and might reduce
adverse effects through lowering the dose.
Worldwide, there is an increase in multiple drug-resistant
tuberculosis (MDR-TB), including reports of outbreaks of
extensive MDR-TB in several countries (4, 36). Patients
suffering from MDR-TB have infections which are resistant
to at least two key drugs in the first-line regimen, namely,
rifampin and isoniazid, in part as a consequence of poor
compliance to the current first-line regimen (approximately
23% of active TB patients presently complete first-line treat-
ment) (5). To treat MDR-TB, other, second-line antibiotics
are needed and therapy lasts up to 2 years, typically requir-
ing parenteral injection (2).
Among the drugs injected is the polypeptide antibiotic cap-
reomycin, the only second-line drug specifically indicated for
MDR-TB. Capreomycin is a complex of four microbiologically
active components that has been shown to be effective in com-
bination with other appropriate anti-TB drugs in the treatment
of pulmonary Mycobacterium tuberculosis infections when the
primary agents (in particular isoniazid and rifampin) have be-
come ineffective as a result of bacterial resistance or toxicity.
The drug is painful to receive by injection and is associated
with serious side effects, such as anorexia, thirst, anemia, and
notably, nephrotoxicity and damage to the auditory and ves-
tibular divisions of cranial nerve VIII (8, 14, 26). The usual
dose for humans is 20 mg/kg of body weight/day (total dose,
1 g) for 60 to 120 days injected intramuscularly (i.m.), posing
significant challenges in delivering a full course to severely
emaciated and chronically ill patients (11).
Targeted drug delivery may maintain local therapeutic con-
centrations and minimize systemic exposure, thus decreasing
side effects. The efficacy of aerosolized rifampin–polylactic-co-
glycolic acid particles (3 to 5 m) for the treatment of pulmo-
nary TB has been reported previously (27, 32, 33). However,
large porous particles (LPPs) are known to aerosolize more
efficiently because they do not readily form aggregates and
they disperse more easily in response to airflow shear forces
than do smaller, nonporous particles. Also, LPPs exhibiting
relatively low water solubility may release drugs into the lung
environment over extended periods of time, since their large
size prevents phagocytosis by macrophages (10).
The main objectives of this study were (i) to determine key
parameters of capreomycin disposition after administration of
powders for inhalation in a guinea pig model of TB and (ii) to
demonstrate the feasibility of pulmonary administration of cap-
reomycin particles and its efficacy in treating TB-infected
guinea pigs, utilizing a novel dry powder formulation that per-
mits room-temperature stability and high-efficiency delivery.
An anticipated advantage of simplified pulmonary delivery is
the elimination of injections, thereby reducing the burden on
clinically qualified personnel for administration of the drug.
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Formulation of capreomycin in LPP powders that possess
optimized aerosol physical properties would allow the drug
to be delivered to the lungs, resulting in enhanced local tissue
concentrations and excellent systemic absorption owing to the
natural absorptive capacity of pulmonary epithelia. Thus, effi-
cacious doses of capreomycin by inhalation may be much lower
than those administered by injection.
MATERIALS AND METHODS
Materials. Leucine was obtained from Sigma-Aldrich (St. Louis, MO), and
acetonitrile, USP-grade ethanol, and methanol were purchased from Pharmco
Products Inc. (Brookfield, CT). Water was obtained from a Millipore Corp.
Milli-Q water purification system (Billerica, MA). Capreomycin sulfate was con-
tributed by Eli Lilly and Co.
Manufacture and characterization of capreomycin particles. Particles for in-
halation were manufactured from a capreomycin solution containing 80% cap-
reomycin sulfate and 20% L-leucine in 50% ethanol, using a Niro Mobile Minor
spray dryer (Columbia, MD) at a feed flow rate of 80 ml/min, with an inlet
temperature of 189 to 192°C, as described elsewhere (10, 34).
The resulting powders were characterized in terms of morphology, volume
diameter, and aerodynamic diameter. Morphology of the particles was visualized
with a LEO 982 field emission scanning electron microscope (Carl Zeiss, Inc.,
Thornwood, NY). Volume diameter was determined by light diffraction using a
HELOS system with a RODOS dry dispersing unit (Sympatec Inc., Law-
renceville, NJ), and aerodynamic diameter was determined using an eight-stage
Andersen Cascade Impactor (Copley Scientific Limited, Nottingham, United
Kingdom). The capreomycin sulfate content in the powders was determined by
high-performance liquid chromatography (HPLC) (1100 series system; Agilent
Technologies, Palo Alto, CA), using a mobile phase consisting of 22:78 metha-
nol-phosphate buffer with 0.3% (wt/wt) heptafluorobutyric acid at 1.0 ml/min and
25°C in a C18 reverse-phase column (Agilent ZORBAX Eclipse XDB-C18
column).
Pharmacokinetic (PK) studies. Male guinea pigs weighing 836  162.3 g were
employed in these studies. Animals were housed with a 12-h light/12-h dark cycle
in a constant-temperature environment of 22°C. A standard diet and water were
supplied ad libitum. All animal procedures were approved by the Institutional
Animal Care and Use Committee of the University of North Carolina. Twenty-
four hours before the study, each animal underwent cannulation of the right
external jugular vein for continuous blood sampling (12).
Animals were randomly divided into five groups receiving capreomycin as
follows: intravenously (i.v.; n  6) and i.m. (n  8) in solution at a dose of 20
mg/kg and as dry powder insufflated by the pulmonary route at low (n  6),
medium (n  6), and high (n  8) nominal doses of 1.4, 7.2, and 14.5 mg/kg.
These doses were based on the dose reduction estimated from direct delivery of
antibiotics to the lungs by insufflation (circumventing oropharyngeal deposition)
and on the practical limitations of easily delivering large masses of dry powders
to the guinea pigs. Blood samples (0.35 ml) were collected from each animal into
heparinized tubes at 0, 0.08, 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 5, 6, 8, and 12 h. After
collection of the last blood sample, animals were euthanized by exsanguination
and bronchoalveolar lavage (BAL) was conducted (5 ml sterile saline).
Plasma and BAL samples were analyzed for drug content by a modified HPLC
assay (29). The limit of detection was 0.5 g/ml, the intraday variation was
8.64%, and the interday variation was 7.15%. The PK parameters area under the
curve (AUC), apparent total body clearance (CL), mean residence time (MRT),
half-life (t1/2), volume of distribution (Vss or V_F), and elimination rate constant
(K) were obtained by noncompartmental methods (WinNonlin; Pharsight Cor-
poration, Mountain View, CA). Maximum capreomycin concentrations (Cmax)
and time to obtain the maximum capreomycin concentration (Tmax) were deter-
mined from the nonfitted plasma-versus-time profile for each individual animal.
Mean absorption time (MAT) was estimated by subtracting the average MRT for
the i.v. group from the MRT of each animal in all other treatment groups.
Pharmacodynamic studies. Animals were infected via the respiratory route
with nebulized suspensions (2  105 CFU/ml) of Mycobacterium tuberculosis
(strain H37Rv), employing an aerosol exposure chamber (University of Wiscon-
sin) (35). Animals remained untreated until 4 weeks following infection, when
the bacterial burden is known to plateau (22). Animals were then assigned to
different groups of six guinea pigs each to receive capreomycin daily for 4 weeks
by i.m. injection or by inhalation using a custom-designed dry powder dosing
chamber.
Prior to pharmacodynamic studies, the aerodynamic particle size of capreo-
mycin particles was characterized by inertial impaction as a measure of delivery
efficiency in the dry powder dosing chamber. Based on a 10% estimated delivery
efficiency (15, 25, 31), the mass of capreomycin particles loaded into the dry
powder dosing chamber was increased 10-fold for daily treatments. The following
six treatment groups were evaluated: i.m. capreomycin solution (20 mg/kg);
inhaled capreomycin LPPs at nominal doses of 1.4, 7.2, and 14.5 mg/kg; inhaled
placebo (leucine:dipalmitoyl-phosphocholine) LPPs; and untreated controls.
Body weights of each animal and changes in behavior or signs of adverse effects
were recorded throughout the study.
Eight weeks after infection and 4 weeks after treatment initiation, animals
were sacrificed and necropsy was performed. The lungs, spleen, and liver were
inspected to determine the number of superficial lesions. The left lung lobe and
a portion of the spleen were placed in 10% neutral buffered formalin for his-
topathological evaluation. For bacteriology, the right lung lobe and the remain-
ing spleen tissue were homogenized. Aliquots of diluted homogenates (lung and
spleen) were inoculated onto M7H10 agar plates (Hardy Diagnostics, Santa
Maria, CA), and plates were incubated at 37°C for 3 weeks. Visible bacterial
CFU (expressed as a logarithm to base 10) were counted.
Formalin-fixed lung and spleen tissues from representative animals in each
group (at least two per group) were submitted for histopathological analysis as a
confirmatory measure of bacteriology. Tissues were embedded in paraffin wax,
sectioned with a microtome (Leica Microsystems, Bannockburn, IL) at 5 m,
and mounted on glass slides. Microscopic examinations were conducted on
hematoxylin-eosin-stained slides for each tissue by a pathologist who was blinded
with respect to the treatment received by any of the animals. The following
parameters were scored: percentage of tissue affected by granulomas, granuloma
size, percentage of granulomas affected by caseous necrosis, amount of caseous
necrosis, and lymphocyte involvement.
Statistical analysis. Data for PK and pharmacodynamic studies were subjected
to analysis of variance and the least-squares significant difference multiple com-
parison method. A probability level of 5% (P  0.05) was considered statistically
significant.
RESULTS
Particle manufacture and characterization. Evaluation by
microscopy showed that capreomycin particles were thin-
walled structures (Fig. 1). The drug content in particles was
59.5%  1.2% (73.8%  1.5% capreomycin sulfate). Sizing
methods revealed particles with a volume diameter of 4.19 
0.05 m and desirable aerodynamic properties for powders
FIG. 1. Scanning electron micrograph of spray-dried capreomycin
dry powder. Bar  5 m.
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that deposit in the respiratory tract, with a mass median aero-
dynamic diameter of 4.99  0.02 m and fine particle fractions
(FPFTD  5.8 m and FPFTD  3.3 m) of 47.7%  0.7%
and  8.8%  0.5%, respectively.
PK studies. Figure 2 shows the average capreomycin plasma
concentration-time curves. For animals treated with capreo-
mycin i.v., the terminal phase of the plasma concentration-time
curves was biphasic, whereas for all other treatments it was
linear and parallel among the different doses. Statistically com-
parable capreomycin concentrations were observed after 1 h
for the i.v. and i.m. groups (Fig. 2) and after 2 h for the i.v.
group and for animals receiving 14.5 mg/kg capreomycin par-
ticles by insufflation (Fig. 2, IS-H). Capreomycin was not de-
tected in the BAL samples from animals in any of the treat-
ment groups, reflecting the efficient absorption of the drug by
the airway epithelium.
PK parameters obtained by noncompartmental methods are
presented in Table 1. The AUC0-t correlated with the capreo-
mycin dose administered, with the i.v. and i.m. groups having
the largest AUC and animals receiving 1 mg of particles by
insufflation having the smallest one. Capreomycin CL was
comparable among animals in all insufflated groups, and that
of animals receiving 14.5 mg/kg of particles was also statisti-
cally comparable to capreomycin CL after i.v. administration.
Capreomycin was eliminated faster (K) when administered i.v.,
i.m., or by insufflation of 1.4 mg/kg of particles than after
insufflation of 7.2 mg/kg of particles. The t1/2 and MRT of
capreomycin were longest after insufflation of 7.2 or 14.5 mg/kg
of particles than those after any other treatment, which can be
correlated with the longer absorption times (MAT) exhibited
by these groups. The absolute bioavailability of capreomycin
after insufflation of 7.2 or 14.5 mg/kg of particles was 59%.
Pharmacodynamic studies. The efficacy of capreomycin for-
mulations delivered by aerosol and injection in the treatment
of TB was evaluated in the guinea pig model. The efficacy of
treatment was measured in terms of reduction of the bacterial
burden in the lungs and spleen and by wet tissue weights and
histopathology as supportive parameters. The TB-infected
guinea pigs tolerated the administration of multiple doses of
FIG. 2. Average plasma concentration-time curves (log scale) after administration of capreomycin at different doses and with different
treatments, namely, capreomycin solution given i.v. and i.m. and capreomycin particles given by insufflation at high (IS-H part), medium (IS-M
part), and low (IS-L part) doses (data are averages  standard deviations; n  6 to 8). Individual animals showed detectable capreomycin plasma
concentrations at 8 h, but the group average was under the limit of detection and thus was not included.
TABLE 1. PK parameters obtained by noncompartmental analysis after administration of different capreomycin






(ml/h  kg) K (h
1) t1/2 (h) MRT (h) Cmax (g/ml) Tmax (h) MAT (h) F0-t
i.v. (20 mg/kg; solution) 49.29  10.712 0.42  0.102,3 0.92  0.101 0.75  0.084 0.88  0.093 53.56  3.931 0.08  0.003 1.00  0.001
i.m. (20 mg/kg; solution) 58.20  10.981 0.35  0.063 0.68  0.181,2,3 1.09  0.303,4 1.44  0.302 32.33  3.752 0.36  0.281 0.44  0.202 1.20  0.231
Insufflation
14.5 mg/kg; powder 16.95  3.943 0.54  0.111,2 0.48  0.132,3 1.53  0.361,2 1.80  0.121 6.70  1.263 0.31  0.121,2 0.80  0.121 0.54  0.112
7.2 mg/kg; powder 8.20  1.454 0.52  0.102 0.45  0.113 1.68  0.371 1.72  0.181 3.34  0.494 0.38  0.141 0.72  0.181 0.59  0.122
1.4 mg/kg; powder 1.15  0.365 0.67  0.251 0.71  0.421,2 1.22  0.562,3 1.01  0.313 0.92  0.385 0.5  0.311 —b 0.41  0.142
a Data are averages  standard deviations (n  6 to 8). Numeric superscripts show the relative ranks of values (starting from the highest values). When the means
are not significantly different, the same superscript is used.
b MAT could not be estimated for this low dose.
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capreomycin solution (i.m.) and capreomycin particles (pulmo-
nary), with no signs of adverse effects.
Wet lung and spleen weights for treated animals were em-
ployed as an indication of the degree of inflammation of each
organ (6, 7, 9, 13, 18, 24). Figure 3 shows the organ weights
corrected by body weight at the time of necropsy. The wet lung
weight of animals receiving 14.5 mg/kg of aerosolized capreo-
mycin particles was significantly smaller than that of untreated
controls and animals receiving 1.4 mg/kg of aerosolized cap-
reomycin particles. In addition, the wet lung weight of animals
receiving 20 mg/kg of capreomycin solution by i.m. injection
was significantly smaller than that of untreated controls. No
significant differences were found in the wet spleen weights of
animals receiving the different treatments.
Figure 4 shows the number of viable bacteria per ml (CFU/
ml) of organ homogenate for lungs and spleens of animals
receiving the different treatments daily for 4 weeks. Animals
receiving an estimated 14.5-mg/kg delivered dose of aerosol-
ized capreomycin particles showed a significantly smaller bac-
terial burden in the lungs (3.52  0.20 CFU/ml; P  0.05) than
did untreated controls (4.58  0.20 CFU/ml), placebo-treated
animals (4.21  0.36 CFU/ml), and animals receiving esti-
mated 1.4- and 7.2-mg/kg delivered doses of aerosolized cap-
reomycin particles (4.02  0.32 and 4.01  0.29 CFU/ml,
respectively). Animals receiving 20 mg/kg capreomycin solu-
tion by i.m. injection also showed a significantly smaller bac-
terial burden in the lungs (3.84  0.34 CFU/ml) than did
untreated controls. These positive results were supported by
histopathological analysis, which revealed that a small percent-
age of the lung lobe was affected by small granulomas in ani-
mals treated with 20 mg/kg i.m. and with 14.5 mg/kg inhaled
capreomycin and that only a few of these granulomas exhibited
caseous necrosis and mild to moderate lymphocyte involve-
ment (Fig. 5).
The bacterial burdens in the spleens of animals receiving
capreomycin i.m. were significantly smaller (at least 1.9-log
reduction) (Fig. 4) than those for any other treatment (P 
0.05), and there were no significant differences among other
treatment groups. Histopathological analysis also indicated a
positive effect in the spleens of these animals and those receiv-
ing the high dose of capreomycin particles compared to other
treatment groups, based on smaller granulomas and a smaller
percentage of white pulp affected by these granulomas (Fig. 6).
DISCUSSION
The primary objective of this study was to demonstrate the
feasibility and viability of simple pulmonary administration of
capreomycin, utilizing a novel and pharmaceutically scaleable
dry powder formulation prepared from materials that allow for
varying the chemical composition, incorporating one or many
drugs into the same particle, therefore enabling therapies that
require combinations of pharmaceutical agents and excipients
(e.g., amino acids, sugars, lipids, and polymers), extended
shelf-life stability, and a controlled particle dissolution rate in
the lungs (1, 17). Low-density powders such as LPPs can be
aerosolized, permitting the efficient delivery of large drug
masses from relatively simple inhalers (30).
The low-inoculum aerosol infection guinea pig model of TB
closely mimics important aspects of the human disease (22).
PK parameters after administration of capreomycin solutions
or suspensions have been determined predominantly for mice
and humans (3, 8, 14, 16, 19–21, 28). There are no reports of
these studies for guinea pigs, a species known to have a dif-
ferent drug disposition from that of other rodents. Further-
more, it is expected that drug disposition will be different in
healthy animals from that in infected animals. The present
studies investigated the disposition of capreomycin in healthy
FIG. 3. Lung and spleen wet weights at necropsy for TB-infected guinea pigs receiving different treatments daily for 4 weeks (data are averages
plus or minus standard deviations; n  6). *, significantly smaller than untreated control values.
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animals to define initial PK parameters, which will require
subsequent evaluation and redefinition in infected animals.
PK studies performed with guinea pigs showed that capreo-
mycin plasma concentrations were higher 2 h after i.v. or i.m.
administration than those for animals receiving the highest
dose of insufflated particles. This initial difference in plasma
concentration was expected given the differences in the nom-
inal doses administered (20 mg/kg versus 14.5 mg/kg); how-
ever, plasma concentrations were comparable among these
groups in the period 2 to 6 h after administration. Moreover,
noncompartmental analysis demonstrated that capreomycin
was cleared (CL) at a lower rate when delivered by the pul-
monary route than when given i.v. or i.m., resulting in a sig-
nificantly longer t1/2. Thus, it was proposed that given the
comparably high drug concentrations in the lungs achieved by
inhalation relative to those reported for other inhaled TB
drugs (34) and the relatively good bioavailability achieved by
inhalation (Table 1), efficacy might be achieved in an infection
FIG. 4. Number of viable bacteria per ml of tissue homogenate (CFU/ml) at necropsy in lung and spleen tissues of TB-infected guinea pigs
receiving the following different treatments daily for 4 weeks: no treatment (untreated controls), i.m. injection of capreomycin (20 mg/kg), placebo
(equivalent to 1.8 mg/kg), and aerosolized capreomycin particles at estimated deposited doses of 0.18, 0.90, and 1.8 mg/kg (corresponding to 1.4-,
7.2-, and 14.5-mg/kg nominal doses, respectively) (data are averages plus or minus standard deviations; n  6). *, significantly smaller than untreated
control values; **, significantly smaller than placebo-treated and untreated control values; #, significantly smaller than the value for any other treatment.
FIG. 5. Lung histopathology of TB-infected guinea pigs. (A) Untreated control; (B) guinea pig receiving 20 mg/kg capreomycin solution i.m.;
(C) guinea pig receiving 1.4 mg/kg capreomycin particles; (D) guinea pig receiving 14.5 mg/kg capreomycin particles. Guinea pigs in groups C and
D received capreomycin particles in the dry powder dispersion chamber by passive inhalation.
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model at an inhaled dose below the dose required to achieve
efficacy by conventional parenteral routes of delivery.
To test this hypothesis, capreomycin was delivered by aero-
sol and injection to guinea pigs in a TB infection model. The
lungs of animals receiving the highest nominal dose of capreo-
mycin particles by passive inhalation in the dry powder dosing
chamber showed significantly smaller degrees of inflammation,
bacterial burdens (CFU/ml), and percentages of lung tissue
affected by granulomas and caseous necrosis (by histopathol-
ogy) than those for any other treatment. In contrast, only
animals treated by i.m. injection showed a significantly reduced
bacterial burden in the spleen; however, histopathological
analysis of spleens revealed a positive effect of treatment with
the high dose of capreomycin particles and the i.m. solution.
Given these results, we postulated that despite the initially
higher systemic concentrations achieved after i.m. administra-
tion, the local capreomycin concentrations in the lung were
higher in animals receiving inhaled powders, resulting in the
reduction of the bacterial burden of the lungs. Although local
concentrations were determined by BAL at the end of the PK
study, determination of capreomycin levels in BAL samples at
earlier time points would be desirable to confirm this assump-
tion. The requirement of terminating the life of an animal for
each time point to acquire BAL samples necessitates a sepa-
rate extensive study, which was considered beyond the scope of
the present work.
The lack of statistical significance in differences in the de-
gree of inflammation and bacterial burden in the lungs and
spleens of animals receiving the medium and low nominal
doses as well as in the spleens of animals receiving the high
dose of capreomycin particles can be explained by the actual
deposited dose of particles in the lungs of these animals. Cap-
reomycin plasma concentration-versus-time profiles as well as
AUC and bioavailability were determined after delivering the
high, medium, and low nominal doses to healthy animals in the
dry powder dispersion chamber. Nominal doses of 14.5 mg/kg
(high), 7.2 mg/kg (medium), and 1.4 mg/kg (low) were deliv-
ered to animals, and it is estimated that they received depos-
ited doses of 1.8, 0.9, and 0.18 mg/kg, respectively. Given these
relatively low deposited doses, the positive responses of reduc-
tions in the bacterial burdens and wet weights of the lungs of
animals receiving the high dose of capreomycin particles by
passive inhalation are noteworthy. The differences in bacterial
burdens and wet weights of the spleens of animals receiving
medium and low doses of particles were statistically insignifi-
cant with respect to untreated controls, which might be antic-
ipated from the low systemic doses achieved by inhalation. In
contrast, statistically significant differences were observed fol-
lowing i.m. administration, where high systemic concentrations
of drug were achieved. While little has been published of
relevance to this subject, a mouse study of inhaled nebulized
capreomycin demonstrated a significantly higher deposited
lung dose than that achieved in the present study (23), result-
ing in a reduction in bacterial burden in the spleen. Therefore,
there is reason to believe that deposition of sufficient drug
(higher than that achieved in the present study) in the lungs of
guinea pigs would potentially result in therapeutic systemic
concentrations.
The results of the present study demonstrate the practical
feasibility of safe and efficacious inhaled capreomycin therapy
as a means of treating TB. The pharmaceutically sound prin-
ciples on which the particles are manufactured are suitable for
immediate clinical trial supply production. Such trials would
demonstrate the utility of pulmonary delivery in the following
FIG. 6. Spleen histopathology of TB-infected guinea pigs. (A) Untreated control; (B) guinea pig receiving 20 mg/kg capreomycin solution i.m.;
(C) guinea pig receiving 1.4 mg/kg capreomycin particles; (D) guinea pig receiving 14.5 mg/kg capreomycin particles. Guinea pigs in groups C and
D received capreomycin particles in the dry powder dispersion chamber by passive inhalation.
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phase I and II studies: (i) a phase Ia, single-dose escalation
study with healthy volunteers, using the inhaled capreomycin
formulation; and (ii) phase Ib/IIa studies with newly diagnosed
MDR-TB patients to observe the fall in serial sputum colony
counts over a period of 16 weeks and to determine the relative
rate of sputum conversion, duration of infectivity, symptom-
atology, and radiography for patients receiving capreomycin
injections versus inhaled capreomycin.
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